Ovid Therapeutics (OVID) Other Non Operating Income (2021 - 2026)

Ovid Therapeutics (OVID) has reported Other Non Operating Income for 6 consecutive years, with $689000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non Operating Income rose 77.12% year-over-year to $689000.0; the trailing twelve-month figure through Jun 2026 stood at $23.9 million (up 603.48% YoY), and the FY2025 full-year result was $25.0 million, down 29.41% from the prior year.
• Other Non Operating Income fell to $689000.0 in Q2 2026 per OVID's latest filing, from $858000.0 in the prior quarter.
• Across five years, Other Non Operating Income topped out at $29.0 million in Q2 2024 and bottomed at -$780000.0 in Q3 2024.
• Historically, Other Non Operating Income has averaged $3.9 million across 5 years, with a median of $847042.5 in 2022.
• The widest YoY moves for Other Non Operating Income: up 1546.15% in 2024, down 200.52% in 2024.
• Over 5 years, Other Non Operating Income stood at $668123.0 in 2022, then surged by 329.11% to $2.9 million in 2023, then sank by 48.76% to $1.5 million in 2024, then surged by 1394.69% to $22.0 million in 2025, then tumbled by 96.86% to $689000.0 in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $689000.0, $858000.0, and $22.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.